Exact Sciences (EXAS) Q3 Revenues Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
UBS Downgrades Exact Sciences (EXAS) to Neutral
October 29, 2020 6:11 AM EDTUBS analyst Dan Brennan downgraded Exact Sciences (NASDAQ: EXAS) from Buy to Neutral with a price target of $140.00 (from $125.00).
The analyst comments "We like the Thrive Deal on many levels, though timelines are lengthy & visibility limited. With COVID-19 pressuring the base business, plus... More
Exact Sciences (EXAS) to Acquire Thrive Earlier Detection for Cash and Stock up to $2.15 Billion
October 27, 2020 7:01 AM EDTExact Sciences Corp. (Nasdaq: EXAS) and Thrive Earlier Detection Corp. ("Thrive"), a healthcare company dedicated to incorporating earlier cancer detection into routine medical care, today announced they have entered into a definitive agreement under which Exact Sciences will acquire Thrive for cash and stock consideration of up to $2.15 billion. The transaction was unanimously approved by both companies' Boards of Directors and is anticipated to close during the first quarter of 2021, subject to regulatory approval and the satisfaction of other conditions.
Combining Thrive's pioneering early-stage screening test, CancerSEEK, with Exact Sciences' best-in-class scientific platform, clinical... More
